163P Development and validation of the prognostic HER2RI assay for predicting recurrence and survival in early HER2-positive breast cancer

Abstract

HER2-positive accounts for 15-20% of breast cancers. Today the decision to escalate or de-escalate systemic therapy for early HER2-positive breast cancer is based primarily on traditional clinical factors, which are insufficient to reflect the molecular complexity and heterogeneity of HER2-positive breast cancer. Here we describe the development and validation of a new HER2RI assay, a model that combines expression data of 16 genes and clinical features to obtain risk values to predict the prognosis of early HER2-positive breast cancer.